Background: A series of open studies suggests that topiramate has efficacy
in bipolar disorder. To further investigate the potential value of topirama
te as an antimanic agent, we conducted an open trial in 11 manic patients.
Method: Eleven patients with bipolar I disorder with an acute manic episode
(DSM-IV) were treated with a mood stabilizer and/or antipsychotics in suff
icient and fixed doses. All had a Young Mania Rating Scale (YMRS) score of
at least 21 (mean +/- SD = 33.5 +/- 8.1). Topiramate was added after stable
plasma levels of concomitant mood stabilizers had been reached and was tit
rated within I week to a final dose in the range of 25 to 200 mg/day, depen
ding on clinical efficacy and tolerability. Topiramate was discontinued aft
er 10 days, while concomitant medication remained unchanged. After 5 days,
topiramate was reintroduced at similar or increased dosages for another 7 d
ays. Patients were assessed with the YMRS; the Clinical Global Impressions
scale version for bipolar patients; and the 21-item Hamilton Rating Scale f
or Depression.
Results: Seven of the 11 patients initially showed a good antimanic respons
e with > 50% reduction in YMRS score. One patient showed psychotic features
following rapid increase in topiramate dosage and dropped out on day 10. A
fter discontinuation of topiramate, 7 of the remaining 10 patients worsened
(increase of greater than or equal to 25% in YMRS score), 2 remained stabl
e, and 1 discontinued follow-up after good recovery. After reintroducing to
piramate. all patients improved again within a week, with a of 9 meeting th
e responder criterion of greater than or equal to 50% YMRS score reduction
when comparing baseline values with those of day 22. With the exception of
the patient who developed psychosis, topiramate was well tolerated. Concomi
tant medication did not interfere with plasma levels of drug, except for ca
rbamazepine level in 1 patient.
Conclusion: The antimanic response among patients in this study appears rep
roducibly linked to the addition of topiramate.